share_log

Ginkgo Bioworks | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Baillie Gifford & Co (Scottish partnership)(14.59%)

Ginkgo Bioworks | SC 13G/A：超过5%持股股东披露文件(修正)-Baillie Gifford & Co (Scottish partnership)(14.59%)

美股sec公告 ·  01/29 22:58
牛牛AI助手已提取核心信息
On December 29, 2023, Baillie Gifford & Co, a Scottish partnership, filed an amended Schedule 13G/A with the SEC, indicating a significant ownership stake in Ginkgo Bioworks Holdings, Inc. The filing revealed that Baillie Gifford & Co holds 236,292,183 shares of Ginkgo Bioworks, representing 14.59% of the company's Class A Common Stock. The shares are held on behalf of various investment advisory clients, including Scottish Mortgage Investment Trust PLC, which is managed by Baillie Gifford & Co Limited, a subsidiary of Baillie Gifford & Co. The filing, which falls under Rule 13d-1(b), asserts that the shares were acquired in the ordinary course of business and not with the intent to change or influence the control of Ginkgo Bioworks. The compliance manager of Baillie Gifford & Co, Grant Meikle, signed the statement on January 16, 2024, certifying the accuracy of the information provided.
On December 29, 2023, Baillie Gifford & Co, a Scottish partnership, filed an amended Schedule 13G/A with the SEC, indicating a significant ownership stake in Ginkgo Bioworks Holdings, Inc. The filing revealed that Baillie Gifford & Co holds 236,292,183 shares of Ginkgo Bioworks, representing 14.59% of the company's Class A Common Stock. The shares are held on behalf of various investment advisory clients, including Scottish Mortgage Investment Trust PLC, which is managed by Baillie Gifford & Co Limited, a subsidiary of Baillie Gifford & Co. The filing, which falls under Rule 13d-1(b), asserts that the shares were acquired in the ordinary course of business and not with the intent to change or influence the control of Ginkgo Bioworks. The compliance manager of Baillie Gifford & Co, Grant Meikle, signed the statement on January 16, 2024, certifying the accuracy of the information provided.
2023年12月29日，苏格兰合伙企业Baillie Gifford & Co向美国证券交易委员会提交了经修订的附表13G/A，表明银杏生物控股公司拥有大量所有权。该文件显示，Baillie Gifford & Co持有银杏生物工程的236,292,183股股份，占该公司A类普通股的14.59％。这些股票代表各种投资咨询客户持有，包括苏格兰抵押贷款投资信托有限公司，该公司由Baillie Gifford & Co.的子公司Baillie Gifford & Co. Limited管理。该文件属于规则13d-1（b）的范围，声称这些股份是在正常业务过程中收购的，无意改变或影响对Ginkgo Bioworks的控制权。Baillie Gifford & Co的合规经理格兰特·梅克尔于2024年1月16日签署了该声明，证明了所提供信息的准确性。
2023年12月29日，苏格兰合伙企业Baillie Gifford & Co向美国证券交易委员会提交了经修订的附表13G/A，表明银杏生物控股公司拥有大量所有权。该文件显示，Baillie Gifford & Co持有银杏生物工程的236,292,183股股份，占该公司A类普通股的14.59％。这些股票代表各种投资咨询客户持有，包括苏格兰抵押贷款投资信托有限公司，该公司由Baillie Gifford & Co.的子公司Baillie Gifford & Co. Limited管理。该文件属于规则13d-1（b）的范围，声称这些股份是在正常业务过程中收购的，无意改变或影响对Ginkgo Bioworks的控制权。Baillie Gifford & Co的合规经理格兰特·梅克尔于2024年1月16日签署了该声明，证明了所提供信息的准确性。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

译文内容由第三方软件翻译。


牛牛AI助手部分由第三方人工智能模型基于资讯内容自动生成，只对中国内地以外的地区提供。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。